Zhejiang Cancer Hospital
🇨🇳China
Individualized Pharmaceutical-care for Inpatients With Cancer Pain
Not Applicable
- Conditions
- Cancer Pain
- Interventions
- Other: pharmaceutical care
- First Posted Date
- 2018-03-06
- Last Posted Date
- 2019-01-15
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 500
- Registration Number
- NCT03455023
- Locations
- 🇨🇳
Zhejiang cancer hospital, Hangzhou, Zhejiang, China
Individualized Pharmaceutical-care in Outpatients With Cancer Pain
Not Applicable
- Conditions
- Cancer Pain
- Interventions
- Other: Pharmaceutical care
- First Posted Date
- 2018-02-20
- Last Posted Date
- 2019-01-15
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT03439904
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Hippocampus Avoidance During Intensity Modulated Radiotherapy for T4 Nasopharyngeal Carcinoma Patients
- Conditions
- Nasopharyngeal Carcinoma
- First Posted Date
- 2018-01-26
- Last Posted Date
- 2018-01-26
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT03411954
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Different Radiation Dose of Neoadjuvant Chemoradiation for Resectable Thoracic Esophageal Squamous Carcinoma
Not Applicable
Completed
- Conditions
- Neoadjuvant ChemoradiotherapyEsophageal CarcinomaSurgery
- Interventions
- Radiation: Higher dose (50.4Gy/28F) of neoadjuvant chemoradiationRadiation: Lower dose (41.4Gy/23F) of neoadjuvant chemoradiation
- First Posted Date
- 2017-12-22
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 147
- Registration Number
- NCT03381651
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Remifemin Preventing the Climacteric Symptoms in Breast Cancer
Phase 2
Completed
- Conditions
- Effect of DrugsSafety Issues
- Interventions
- Drug: Remifemin
- First Posted Date
- 2017-11-13
- Last Posted Date
- 2018-07-06
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 85
- Registration Number
- NCT03339882
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
DEB-TACE Treatment in 367 Liver Cancer Patients
Completed
- Conditions
- Liver Cancer
- First Posted Date
- 2017-10-23
- Last Posted Date
- 2017-10-23
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 367
- Registration Number
- NCT03317483
A Prospective Validation Cohort Study of a Prediction System on nSLN Metastasis in Early Breast Cancer
Not Applicable
- Conditions
- Breast CancerLymph Node MetastasesPredictive Cancer Model
- Interventions
- Procedure: axillary lymph node dissection (ALND)
- First Posted Date
- 2017-09-12
- Last Posted Date
- 2019-06-04
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 388
- Registration Number
- NCT03280134
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Apatinib in Combination With S-1 as Second-Line Treatment in Patients With Advanced Gastric Cancer
- First Posted Date
- 2017-09-08
- Last Posted Date
- 2017-09-08
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT03276156
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Apatinib in Treating Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
- First Posted Date
- 2017-07-11
- Last Posted Date
- 2017-07-11
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 51
- Registration Number
- NCT03213587
- Locations
- 🇨🇳
Xiaozhong Chen, Hangzhou, Zhejiang, China
Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen at Least 2nd Line in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer
- First Posted Date
- 2017-07-02
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 132
- Registration Number
- NCT03204734
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
© Copyright 2025. All Rights Reserved by MedPath